vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and Synopsys (SNPS). Click either name above to swap in a different company.
Synopsys is the larger business by last-quarter revenue ($2.3B vs $1.2B, roughly 1.9× Jazz Pharmaceuticals plc). Synopsys runs the higher net margin — 19.9% vs 17.0%, a 2.9% gap on every dollar of revenue. On growth, Synopsys posted the faster year-over-year revenue change (50.6% vs 10.1%). Synopsys produced more free cash flow last quarter ($605.2M vs $345.8M). Over the past eight quarters, Synopsys's revenue compounded faster (16.9% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Synopsys, Inc. is an American multinational electronic design automation (EDA) company headquartered in Sunnyvale, California, that focuses on design and verification of silicon chips, electronic system-level design and verification, and reusable components. Synopsys supplies tools and services to the semiconductor design and manufacturing industry.
JAZZ vs SNPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.3B |
| Net Profit | $203.5M | $448.7M |
| Gross Margin | — | 71.0% |
| Operating Margin | 21.2% | 5.4% |
| Net Margin | 17.0% | 19.9% |
| Revenue YoY | 10.1% | 50.6% |
| Net Profit YoY | 6.5% | -59.7% |
| EPS (diluted) | $3.34 | $2.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.3B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $897.8M | $1.5B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.0B | $1.5B | ||
| Q1 24 | $902.0M | $1.6B |
| Q4 25 | $203.5M | $448.7M | ||
| Q3 25 | $251.4M | $242.5M | ||
| Q2 25 | $-718.5M | $345.3M | ||
| Q1 25 | $-92.5M | $295.7M | ||
| Q4 24 | $191.1M | $1.1B | ||
| Q3 24 | $215.1M | $408.1M | ||
| Q2 24 | $168.6M | $292.1M | ||
| Q1 24 | $-14.6M | $449.1M |
| Q4 25 | — | 71.0% | ||
| Q3 25 | — | 78.1% | ||
| Q2 25 | — | 80.2% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 78.3% | ||
| Q3 24 | — | 80.9% | ||
| Q2 24 | — | 79.4% | ||
| Q1 24 | — | 80.0% |
| Q4 25 | 21.2% | 5.4% | ||
| Q3 25 | 5.1% | 9.5% | ||
| Q2 25 | -65.6% | 23.5% | ||
| Q1 25 | -6.2% | 17.3% | ||
| Q4 24 | 17.5% | 20.3% | ||
| Q3 24 | 24.7% | 23.6% | ||
| Q2 24 | 19.5% | 22.8% | ||
| Q1 24 | 7.3% | 21.8% |
| Q4 25 | 17.0% | 19.9% | ||
| Q3 25 | 22.3% | 13.9% | ||
| Q2 25 | -68.7% | 21.5% | ||
| Q1 25 | -10.3% | 20.3% | ||
| Q4 24 | 17.6% | 74.4% | ||
| Q3 24 | 20.4% | 26.7% | ||
| Q2 24 | 16.5% | 20.1% | ||
| Q1 24 | -1.6% | 27.2% |
| Q4 25 | $3.34 | $2.44 | ||
| Q3 25 | $4.08 | $1.50 | ||
| Q2 25 | $-11.74 | $2.21 | ||
| Q1 25 | $-1.52 | $1.89 | ||
| Q4 24 | $2.97 | $7.13 | ||
| Q3 24 | $3.42 | $2.61 | ||
| Q2 24 | $2.49 | $1.88 | ||
| Q1 24 | $-0.23 | $2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $3.0B |
| Total DebtLower is stronger | $5.4B | $13.5B |
| Stockholders' EquityBook value | $4.3B | $28.3B |
| Total Assets | $11.7B | $48.2B |
| Debt / EquityLower = less leverage | 1.24× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $3.0B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.2B | $14.3B | ||
| Q1 25 | $1.9B | $3.8B | ||
| Q4 24 | $2.4B | $4.1B | ||
| Q3 24 | $2.2B | $2.0B | ||
| Q2 24 | $1.4B | $1.7B | ||
| Q1 24 | $1.4B | $1.3B |
| Q4 25 | $5.4B | $13.5B | ||
| Q3 25 | $5.4B | $14.3B | ||
| Q2 25 | $5.4B | $10.1B | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $28.3B | ||
| Q3 25 | $4.0B | $27.6B | ||
| Q2 25 | $3.7B | $9.9B | ||
| Q1 25 | $4.2B | $9.3B | ||
| Q4 24 | $4.1B | $9.0B | ||
| Q3 24 | $4.2B | $7.7B | ||
| Q2 24 | $3.8B | $7.2B | ||
| Q1 24 | $3.7B | $6.7B |
| Q4 25 | $11.7B | $48.2B | ||
| Q3 25 | $11.4B | $48.2B | ||
| Q2 25 | $10.9B | $23.8B | ||
| Q1 25 | $11.5B | $13.0B | ||
| Q4 24 | $12.0B | $13.1B | ||
| Q3 24 | $12.3B | $11.6B | ||
| Q2 24 | $11.4B | $11.0B | ||
| Q1 24 | $11.3B | $10.6B |
| Q4 25 | 1.24× | 0.48× | ||
| Q3 25 | 1.35× | 0.52× | ||
| Q2 25 | 1.45× | 1.01× | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $639.7M |
| Free Cash FlowOCF − Capex | $345.8M | $605.2M |
| FCF MarginFCF / Revenue | 28.9% | 26.8% |
| Capex IntensityCapex / Revenue | 1.4% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.78× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $639.7M | ||
| Q3 25 | $474.6M | $671.0M | ||
| Q2 25 | $88.9M | $275.4M | ||
| Q1 25 | $429.8M | $-67.5M | ||
| Q4 24 | $398.6M | $562.8M | ||
| Q3 24 | $398.7M | $455.4M | ||
| Q2 24 | $331.4M | $476.6M | ||
| Q1 24 | $267.2M | $-87.8M |
| Q4 25 | $345.8M | $605.2M | ||
| Q3 25 | $459.4M | $632.4M | ||
| Q2 25 | $75.9M | $219.8M | ||
| Q1 25 | $415.9M | $-108.2M | ||
| Q4 24 | $385.3M | $558.4M | ||
| Q3 24 | $388.0M | $415.4M | ||
| Q2 24 | $324.3M | $438.2M | ||
| Q1 24 | $260.3M | $-128.2M |
| Q4 25 | 28.9% | 26.8% | ||
| Q3 25 | 40.8% | 36.3% | ||
| Q2 25 | 7.3% | 13.7% | ||
| Q1 25 | 46.3% | -7.4% | ||
| Q4 24 | 35.4% | 37.3% | ||
| Q3 24 | 36.8% | 27.2% | ||
| Q2 24 | 31.7% | 30.1% | ||
| Q1 24 | 28.9% | -7.8% |
| Q4 25 | 1.4% | 1.5% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 1.2% | 3.5% | ||
| Q1 25 | 1.5% | 2.8% | ||
| Q4 24 | 1.2% | 0.3% | ||
| Q3 24 | 1.0% | 2.6% | ||
| Q2 24 | 0.7% | 2.6% | ||
| Q1 24 | 0.8% | 2.4% |
| Q4 25 | 1.78× | 1.43× | ||
| Q3 25 | 1.89× | 2.77× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | -0.23× | ||
| Q4 24 | 2.09× | 0.51× | ||
| Q3 24 | 1.85× | 1.12× | ||
| Q2 24 | 1.97× | 1.63× | ||
| Q1 24 | — | -0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
SNPS
| License And Maintenance | $940.7M | 42% |
| Other | $640.0M | 28% |
| Design IP Segment | $407.1M | 18% |
| KR | $236.9M | 11% |
| Sales Based Royalties | $30.1M | 1% |
